Titles
- Confronting COVID-19 vaccine hesitancy among nonelderly adults: findings from the December 2020 Well-Being and Basic Needs Survey1
- Confronting costs: stabilizing U.S. health spending while moving toward a high performance health care system1
- Confronting rural America’s health care crisis: BPC Rural Health Task Force policy recommendations1
- Connect, collaborate, communicate: the story of the EDM Forum1
- Connecticut Medicaid Fraud Control Unit: 2021 inspection1
- Connecticut implemented our prior audit recommendations and generally complied with federal and state requirements for reporting and monitoring critical incidents1
- Connecting kids to health coverage: evaluating the Child Health and Disability Prevention Gateway program1
- Connecting remote cardiac monitoring issues with care areas1
- Connecting the justice-involved population to Medicaid coverage and care: findings from three states1
- Connecting undocumented New Yorkers to coverage1
- Consent-to-share: California’s opportunity to modernize cross-sector data sharing1
- Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff1
- Considerations for a local health insurance option in Medicaid non-expansion states1
- Considerations for building federal data capacity for patient-centered outcomes research related to intellectual and developmental disabilities1
- Considerations for defining rural places in health policies and programs1
- Considerations for design, development, and analytical validation of next generation sequencing (NGS)--based in vitro diagnostics (IVDs) intended to aid in the diagnosis of suspected germline diseases: guidance for stakeholders and Food and Drug Administration staff1
- Considerations for the conduct of clinical trials of medical products during major disruptions due to disasters and public health emergencies: guidance for industry, investigators, and institutional review boards1
- Considerations for the development of dried plasma products intended for transfusion1
- Considerations for the inclusion of adolescent patients in adult oncology clinical trials1
- Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry1